LataMed AI and FARMASER Partner to Revolutionize Pharmacy Operations with AI

LataMed AI Corp. (OTC: LMED) has signed a memorandum of understanding with Venezuelan pharmacy chain FARMASER to develop a customized artificial intelligence and automation platform aimed at enhancing pharmacy operations and supporting expansion. The collaboration will focus on designing software tailored to FARMASER's workflows, including e-commerce, prescription management, customer service, inventory planning, and business analytics. Notably, LataMed AI plans to integrate its AI-powered health models—CardioAI, PulmoAI, and NeuroAI—across FARMASER's three existing stores and up to 15 planned new locations, which could provide patients with access to cardiovascular, pulmonary, and neurological health information and digital health services, pending regulatory approvals and clinical protocols.

Dr. Kevin Rodan Levy, CEO of LataMed AI, emphasized that pharmacies are a critical part of the healthcare ecosystem, and this partnership aims to build a platform that supports both current operations and future growth. The proposed platform would also represent an enterprise application of LataMed AI's technology beyond its patient-facing telemedicine services, potentially creating a scalable infrastructure for other healthcare organizations across Latin America. The parties are evaluating an annual software licensing or subscription model for commercial implementation, though terms remain subject to further development and testing.

This initiative aligns with LataMed AI's broader strategy to create an integrated healthcare ecosystem connecting patients, healthcare professionals, pharmacies, insurers, and payment providers. However, the company cautions that the memorandum does not guarantee successful deployment, revenue generation, or regulatory approval. For additional information, visit https://latamed.ai and review SEC filings at www.sec.gov. The original release is available on NEWMEDIAWIRE.